Latest News

Acquiring advanced certifications equips pharmacy technicians with a clear pathway to increased salary potential and long-term financial stability.

Real-world data show racial gaps in multiple myeloma CAR T-cell therapy; pharmacists in oncology can boost referrals, equity, and access.

RUNX1 in microglia helps predict opioid pain relief, higher morphine needs, and withdrawal severity—pointing to genetic screening and safer, personalized pain management.

New once-daily oral peptide blocks IL‑23 receptor, delivering high skin clearance and strong safety for moderate-to-severe plaque psoriasis in ages 12+.

Daily walking and resistance bands during chemotherapy help curb chemo brain and brain fog, keeping patients active and sharper at home.

Finerenone slows non-diabetic chronic kidney disease, improving eGFR slope and signaling a possible FDA expansion.

Analysis reveals critical price volatility patterns affecting pharmacy inventory management.

A Response to “We Can Do Better: Educating on Perimenopause and Menopause Is a Good Thing,” Published in November 2025

The VIVID trial finds high-dose vitamin D3 doesn’t cut COVID care visits but hints at fewer long COVID symptoms.

Novo Nordisk's Nicky Kelepouris, MD, discusses the REAL8 trial, the expanded pediatric indications for once-weekly somapacitan, and the pharmacist's role in supporting families navigating long-term growth hormone therapy.

Improved risk stratification for coadministration of linezolid with serotonergic agents has the potential to optimize its indications in clinical practice.

Stopping weight management medications drives rapid weight regain and metabolic rebound—making long-term treatment key to optimal outcomes.

Tabitha Peterson, PharmD, discusses how teamwork, strategy, and antidoping expertise sharpen patient care and athlete safety.

Build financial confidence by making strategic money decisions all year.

ADCs are reshaping metastatic breast cancer and pharmacists' roles in treatment management.

Mass-produced compounded GLP-1 drugs bypass FDA safeguards, raising sterility, quality, and supply-chain risks—putting patients at risk despite ending shortages.

FDA approves secukinumab for adolescents 12 years and older with moderate to severe hidradenitis suppurativa, offering the first IL-17A option and new hope for earlier relief.

FDA expands Arexvy RSV vaccine to at-risk adults 18-49, backed by phase 3b data—what it means for patients and pharmacists.

No FDA-approved oral suspension of valacyclovir currently exists, meaning pharmacies must continue relying on compounded preparations for patients unable to swallow tablets while Hyloris works to resolve the manufacturing issues.

Although the rates of gabapentin use without a prescription were nearly double those of prescribed use, the trends are decreasing over time.

An Intermountain Health study finds atrial fibrillation present in 25% of patients with peripheral arterial disease, with major cardiovascular events occurring in 46% within 3 years.